MMV390048

DRUG2 trials

Sponsors

Medicines for Malaria Venture

Conditions

MalariaMalaria,Falciparum

Phase 1

Chemoprotective Activity of MMV390048 in PfSPZ Challenge Model

WithdrawnNCT03195387

Medicines for Malaria VentureMalaria,Falciparum

Start: 2018-01-31End: 2018-12-31Updated: 2018-02-05

Phase 2

MMV390048 POC in Patients With P. Vivax and P. Falciparum Malaria

TerminatedNCT02880241

Medicines for Malaria VentureMalaria

Start: 2017-10-20End: 2018-09-24Updated: 2021-12-09

Related Papers

A Phase 1, Placebo-controlled, Randomized, Single Ascending Dose Study and a Volunteer Infection Study to Characterize the Safety, Pharmacokinetics, and Antimalarial Activity of the <i>Plasmodium</i> Phosphatidylinositol 4-Kinase Inhibitor MMV390048

Clinical Infectious Diseases2020-04-0154 citations

Safety, Tolerability, Pharmacokinetics, and Antimalarial Activity of the Novel <i>Plasmodium</i> Phosphatidylinositol 4-Kinase Inhibitor MMV390048 in Healthy Volunteers.

2020-03-2450 citations